HCG Eyes 1,000-Bed Expansion As Margins Rise To 19.4%

HealthCare Global Enterprises (HCG) is seeing a shift in its business performance under the leadership of CEO Dr. Manish Mattoo. In the first quarter of the 2027 fiscal year, the company reported a 13.4% year-on-year increase in revenue, reaching ₹695.1 crore. This growth was accompanied by a rise in profitability, with adjusted EBITDA margins reaching 19.4%.

Since taking charge in mid-2025, Dr. Mattoo has prioritized streamlining the company’s finances and sharpening its focus on oncology, the chain's core specialty. A major part of this turnaround involved the divestment of Milann, its non-core fertility business. The funds raised from this exit, along with capital from a rights issue, have been directed toward reducing debt and strengthening the balance sheet. This deleveraging effort has given the company more financial freedom to focus on its hospital operations.

Operational Focus and Margin Improvement

The improvement in margins is driven by changes in how the hospitals handle patients. The company has worked to increase the rate at which outpatient visits convert into inpatient admissions, now reaching approximately 20%. By focusing on complex oncology treatments and improving clinical outcomes, HCG is seeing higher-value patients. The share of revenue coming from cash and insurance patients has also grown to nearly 69%, which generally supports more stable cash flows compared to government-scheme patients.

Management has set an ambitious target to reach EBITDA margins of 21% to 22% within the next two years. Achieving this will depend on the company’s ability to manage costs effectively while maintaining the quality of care. The business is also investing in high-end medical technology, such as surgical robots and advanced scanning equipment, to attract more patients and justify its service offerings.

Growth Strategy and Capacity Expansion

The company is betting on a large expansion phase, with a target to add 1,000 beds to its network by FY30. This growth is expected to come primarily from brownfield projects—expanding existing facilities—rather than building everything from scratch. This approach is often more cost-effective and faster to execute.

However, the expansion brings its own set of risks. Building and filling new capacity requires significant capital and time. Investors will likely monitor how well the company manages these projects to avoid cost overruns or delays. Additionally, the broader hospital sector in India faces ongoing pressure from regulatory bodies regarding the pricing of hospital rooms, medical tests, and specific procedures. Any new government-imposed caps on pricing could affect the margins that the company is currently working to improve.

Competition remains intense in the Indian hospital space, with many large players aggressively adding capacity. HCG will need to ensure that its specific focus on oncology provides a strong enough advantage to maintain its patient base and pricing power as it scales up. The key monitoring points for shareholders will be the pace of bed commissioning, the actual margin trajectory in the coming quarters, and the company's ability to maintain a healthy balance sheet while funding its expansion.